Epigenetic alterations of p15INK4B and p16INK4A genes in pediatric primary myelodysplastic syndrome

Leukemia and Lymphoma

Volumn 51, Issue 10, 2010, Pages 1887-1894

  Rodrigues, Eliane F ^a,b   Santos Rebouças, Cntia B ^b   Gonçalves Pimentel, Mrcia M ^b   Mencalha, Andre L ^a   Dobbin, Jane ^a   Da Costa, Elaine S ^c   Fernandez, Ceclia De Souza ^d   Bouzas, Luis F ^a   Abdelhay, Eliana ^a   De Souza Fernandez, Teresa ^a,b  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

epigenetic; methylation; P15INK4B gene; P16INK4A gene; pediatric myelodysplastic syndrome

Indexed keywords

BIOLOGICAL MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHROMOSOME 15P; CHROMOSOME 16P; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; INFANT; MALE; METHYLATION; MYELODYSPLASTIC SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; SCHOOL CHILD;

ADOLESCENT; ANALYSIS OF VARIANCE; BASE SEQUENCE; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; HUMANS; INFANT; MALE; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77957741934     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.505820     Document Type: Article

References (26)

1. Nimer SD. Myelodysplastic syndromes. Blood 2008;111: 4841-4851.
2. Niemeyer CM, Baumann I. Myelodysplastic syndrome in children and adolescents. Semin Hematol 2008;45:60-70.
3. Elghetany MT. Myelodysplastic syndromes in children: a critical review of issues in the diagnosis and classification of 887 cases from 13 published series. Arch Pathol Lab Med 2007;131:1110-1116.
4. Hasle H, Niemeyer CM, Chessels JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003;17:277-282.
5. Polychronopoulou S, Panagiotou JP, Kossiva L, Mavrou A, Anagnostou D, Haidas S. Clinical and morphological features ofpaediatric myelodysplastic syndromes: a review of 34 cases. Acta Paediatr 2004;93:1015-1023.
6. Paluszczak J, Baer-Dubowska W. Epigenetic diagnostics of cancer-the application of DNA methylation markers. J Appl Genet 2006;47:365-375.
7. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 2008;68:1-11.
8. I characterize the major types of hematologcal malignancies. CancerRes 1997;57:837-841.
9. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood 2001;97:2823-2829.
10. NK4B p15 and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leuk Res 2005;29:653-659.
11. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
12. p15INK4B gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998;8:2985-2990.
13. p15INK4B gene in myelodysplastic syndrome: it can be detected early or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001;112: 148-154.
14. I, HIC1, CDH1 and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006; 76:23-32.
15. Hasegawa D, Manabe A, Kubota T, et al. Methylation status of the p15 and p16 genes in paedriatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia. Br J Haematol 2005;128:805-812.
16. Vidal DO, Paixão VA, Brait M, et al. Aberrant methylation in pediatric myelodysplastic syndrome. Leuk Res 2007;31:175-181.
17. Herman J, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93: 9821-9826.
18. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997;25:2532-2534.
19. Brakensiek K, Länger F, Schlegelberger B, Kreipe H, Lehmann U. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol 2005;130:209-217.
20. Uchida T, Kinoshita T, Nagai H, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997;90:1403-1409.
21. Solomon PR, Munirajan AK, Tsuchida N, et al. Promoter hypermethylation analysis in myelodysplastic syndromes: diagnostic and prognostic implications. Indian J Med Res 2008;127:52-57.
22. Flotho C. Is childhood MDS an epigenetic disease? Leuk Res 2007;31:743.
23. Sheng XM, Kawamura M, Ohnishi H, et al. Mutations of the RAS genes in childhood acute myeloid leukemia, myelodys-plastic syndrome and juvenile chronic myelocytic leukemia. LeukRes 1997;21:697-701.
24. Fernandez TS, Menezes J, Silva MLM, Tabak D, Abdelhay E. Correlation of N-ras point mutations with specific chromoso-mal abnormalities in primary myelodysplastic syndrome. Leuk Res 1998;22:125-134.
25. Jeki B, Novakovic I, Lukovic L, et al. Low frequency of NRAS and KRAS2 gene mutations in childhood myelodysplastic syndromes. Cancer Genet Cytogenet 2004;154:180-182.
26. Jiang Y, Dunbar A, Lukasz P, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113:1315-1325.